

News release via Canada NewsWire, Vancouver 604-669-7764

Medifocus Inc. announces new Director

VANCOUVER, April 1 /CNW/ - April 1, 2009 - Medifocus Inc. ("Medifocus") is pleased to announce that Grant Walsh was appointed to the Board of Directors of Medifocus.

Mr. Walsh is the managing partner and Chief Executive Officer of EC Murphy Walsh, a management consulting firm specializing in performance improvement in service, healthcare and health related organizations.

Prior to establishing EC Murphy Walsh, Mr. Walsh was the President and Chief Executive Officer of St. Peter's Health System in Ontario, a regional provider of integrated healthcare services.

Previously, Mr. Walsh was an Executive Vice President with ServiceMaster Management Services, and oversaw 30,000 employees servicing 10,000 client properties in 44 states.

Mr. Walsh is an Adjunct Professor in the Executive Education program at the DeGroote School of Business, McMaster University and has received from The DeGroote School of Business and the Conference Board of Canada the designation as a Chartered Director.

Dr. Augustine Cheung, Chairman of the Board, indicates that Mr. Walsh will assist in the growth of Medifocus due to his significant experience and success in the healthcare and health related sectors: "We are pleased to welcome Grant to the board and are looking forward to benefiting from his wealth of experience and knowledge."

Mr. Walsh joins the Medifocus Board comprised of Dr. Augustine Cheung, Dr. Andy Lam and Joe K.F. Tai. At this time the directors of Medifocus believe that the current number of directors is appropriate and cost-effective with respect to the size and development stage of Medifocus as well as the needs of its shareholders.

The directors and senior management of Medifocus have held a series of meetings with investors in Toronto last week following a press conference held on March 25 at which Dr. Augustine Cheung provided an update on the recent corporate and scientific developments for Medifocus. Dr. Cheung informed the investors and stakeholders present that Medifocus is waiting for clearance from the Research Ethics Boards (REB) of the Ville Marie Medical Center in Montreal and of the North York General Hospital in Toronto to start its Pivotal Phase-II trial on breast cancer in Canada. In addition, Dr. Cheung

also summarized the clinical results of two randomized phase-II studies on breast cancer which were reported by others during the recent 19th Annual National Interdisciplinary Breast Center Conference in Las Vegas.

The TSX also held a market opening ceremony for Medifocus on March 25, 2009.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

%SEDAR: 00023463E

/For further information: Dr. Augustine Cheung, Chairman and Chief Executive Officer, Telephone (410) 290-5734; IR/PR Inquiry, NAI Interactive Ltd., Jessie Song, Telephone: (604) 488-8878, 1-866-833-5517/
(MFS.P.)